Explore

Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
Trendline Trendline
Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition

Novo Nordisk Expands GLP-1 Drug Portfolio Amid Rising Market Competition
TheStreet TheStreet
Morgan Stanley uncovers major Bristol Myers stock signals

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Trendline Trendline
Eli Lilly Stock Anticipates Volatility Ahead of Earnings Release

Eli Lilly Stock Anticipates Volatility Ahead of Earnings Release

Eli Lilly Stock Anticipates Volatility Ahead of Earnings Release
Reuters Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
TheStreet TheStreet
Deutsche Bank sees jarring signs in Roblox as stock crashes

Deutsche Bank sees jarring signs in Roblox as stock crashes

Roblox (RBLX) stock fell hard over the past year, but its user base kept growing, and plenty of investors were willing to wait for a turnaround. That patience ran out on July 31. Roblox reported second-quarter results, then told the market something concerning.  The company expects its ...
Trendline Trendline
Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success
Trendline Trendline
Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies

Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies

Eli Lilly Outperforms Novo Nordisk Amid Diverging Financial Strategies
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
Pfizer and Eli Lilly Present Diverging Investment Opportunities in Pharma

Pfizer and Eli Lilly Present Diverging Investment Opportunities in Pharma

Pfizer and Eli Lilly Present Diverging Investment Opportunities in Pharma
Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Fails in Phase 3 Cardiovascular Trial, Shares Drop